iSERA Lifesciences Ltd
iSERA Lifesciences Ltd (ISERA) last reported results for the quarter ended Jun 2019, with sales of ₹1.11 crore and net profit of ₹-0.06 crore. The stock last traded at ₹144, a market capitalisation of ₹354 crore. Over the past 52 weeks the stock has ranged between ₹7.99 and ₹151. Figures are as of 6 Oct 2026 and are not real time.
iSERA Lifesciences Ltd share price and key metrics
- Current price
- ₹144
- Market cap
- ₹354 cr
- Book value
- ₹0.02
- ROE
- -7.92%
- ROCE
- 3.40%
- Dividend yield
- 0.00%
- 52w high / low
- 151/7.99
Metrics as of 6 Oct 2026. Not real time.
Track iSERA Lifesciences Ltd
Cruxal reads every iSERA Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
iSERA Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- -6%
- 3 Years
- 0%
- TTM
- -23%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -13%
- TTM
- -500%
- 10 Years
- 40%
- 5 Years
- 170%
- 3 Years
- 313%
- 1 Year
- 1558%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- -8%
iSERA Lifesciences Ltd quarterly results
In the quarter ended Jun 2019, sales were ₹1.11 cr, down 89.4% from ₹10.43 cr a year earlier. Net profit swung to a loss of ₹0.06 cr.
| ₹ crore | Jun 2015 | Sep 2015 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4.43 | 6.24 | 13.79 | 10.43 | 7.42 | 4.21 | 3.62 | 1.11 |
| Expenses | 4.23 | 6.02 | 13.59 | 10.35 | 7.32 | 4.12 | 3.41 | 1.11 |
| Operating profit | 0.2 | 0.22 | 0.2 | 0.08 | 0.1 | 0.09 | 0.21 | 0 |
| OPM % | 4.51% | 3.53% | 1.45% | 0.77% | 1.35% | 2.14% | 5.80% | 0.00% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0.09 | 0.05 | 0.11 | 0.09 | 0.13 | 0.06 |
| Depreciation | 0.09 | 0.09 | 0.12 | 0 | 0.02 | 0.01 | 0.09 | 0 |
| Profit before tax | 0.11 | 0.13 | -0.01 | 0.03 | -0.03 | -0.01 | -0.01 | -0.06 |
| Tax % | 27.27% | 30.77% | -100.00% | 33.33% | 0.00% | 0.00% | 100.00% | 0.00% |
| Net profit | 0.08 | 0.09 | 0 | 0.02 | -0.03 | -0.01 | -0.03 | -0.06 |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
iSERA Lifesciences Ltd annual results
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 6.29 | 25.85 | 35.89 | 11.06 | 25.5 | 33.57 | 25.69 | 16.36 |
| Operating profit | 0.08 | 3.11 | 0.52 | 0.78 | 0.36 | 0.47 | 0.48 | 0.4 |
| OPM % | 1.27% | 12.03% | 1.45% | 7.05% | 1.41% | 1.40% | 1.87% | 2.44% |
| Net profit | 0.06 | 1.93 | 0.11 | 0.13 | -13.42 | 0.01 | -0.04 | -0.13 |
| EPS (₹) | — | 0.07 | 0.00 | 0.00 | -0.49 | 0.00 | -0.00 | 0.00 |
TTM is the trailing twelve months to the most recent quarter.
iSERA Lifesciences Ltd balance sheet
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|
| Equity capital | 3.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 |
| Reserves | 1.72 | 3.14 | 3.24 | 3.37 | -10.05 | -10.07 | -10.12 |
| Borrowings | 0.00 | 2.35 | 5.64 | 6.33 | 7.51 | 9.51 | 10.64 |
| Other liabilities | 2.00 | 6.15 | 5.76 | 4.52 | 6.41 | 9.88 | 6.54 |
| Total liabilities | 7.32 | 22.24 | 25.24 | 24.82 | 14.47 | 19.92 | 17.66 |
| Fixed assets | 0.07 | 5.56 | 6.37 | 7.90 | 0.71 | 0.61 | 0.87 |
| CWIP | 4.06 | 6.34 | 5.36 | 4.23 | 0.00 | 0.00 | 0.00 |
| Investments | 0.69 | 0.18 | 0.18 | 0.28 | 0.00 | 0.00 | 0.00 |
| Other assets | 2.50 | 10.16 | 13.33 | 12.41 | 13.76 | 19.31 | 16.79 |
| Total assets | 7.32 | 22.24 | 25.24 | 24.82 | 14.47 | 19.92 | 17.66 |
As reported by the company. Total assets equal total liabilities by construction.
iSERA Lifesciences Ltd cash flow
| ₹ crore | Mar 2012 | Mar 2013 | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|
| Cash from operations | -0.03 | -1.94 | 0.49 | 0.81 | -0.65 | -0.33 |
| Cash from investing | 0.00 | -7.44 | -1.16 | -0.40 | -0.16 | -0.38 |
| Cash from financing | 0.00 | 9.45 | 0.69 | -0.42 | 0.80 | 1.13 |
| Net cash flow | -0.03 | 0.07 | 0.03 | -0.01 | -0.01 | 0.42 |
| Free cash flow | -0.03 | -5.43 | 0.09 | 0.41 | -0.65 | -0.33 |
| CFO / operating profit | -38% | -62% | 63% | 225% | -136% | -65% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
iSERA Lifesciences Ltd operating ratios
| Per year | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 27.93% | 1.18% | 0.60% | 1.55% | — | 3.40% |
| Debtor days | 137.53 | 114.65 | 111.36 | 274.58 | 157.16 | 185.27 | 203.31 |
| Inventory days | — | — | — | — | — | 0.00 | 0.00 |
| Cash conversion cycle | 137.53 | 114.65 | 111.36 | 274.58 | 157.16 | 185.27 | 203.31 |
| Working capital days | 29.01 | 55.91 | 77.19 | 260.38 | 81.87 | 83.39 | 102.86 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
iSERA Lifesciences Ltd shareholding pattern
Promoters held 58.63% at Jun 2026, down from 92.76% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 26.35% | 26.35% | 92.76% | 92.76% | 92.76% | 3.57% | 58.63% | 58.63% |
| Public | 73.65% | 73.65% | 7.24% | 7.24% | 7.24% | 96.43% | 41.38% | 41.37% |
| No. of shareholders | 2,530 | 2,530 | 932 | 932 | 936 | 1,034 | 1,029 | 1,014 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
iSERA Lifesciences Ltd corporate filings
- Corporate Share Swap and Capital Reorganization Announced by iSERA Lifesciences LimitedCompany Updatehigh impact
Cruxal's analysis: iSERA Lifesciences Limited has disclosed multiple share swap transactions involving…
Read the full analysis - iSERA Lifesciences Limited Promoter Discloses Preferential Allotment of 4.95 Lakh Shares to Promoter, Increasing Promoter Holding by 2.01% to 8.32%Insider Trading / SASThigh impact
Cruxal's analysis: iSERA Lifesciences Limited's promoter, Archana Kakasaheb Lonkar, has acquired an…
Read the full analysis - iSERA Lifesciences Limited discloses shareholding transfer via share swap, resulting in a 6.39% stake changeInsider Trading / SASTmedium impact
Cruxal's analysis: iSERA Lifesciences Limited has announced a share transfer through a share swap agreement…
Read the full analysis - ISERA Lifesciences Limited completes preferential allotment of approximately 15.66 lakh equity shares, raising around INR 8.40 crore through a share swap at a valuation of INR 24.59 croreInsider Trading / SASThigh impact
Cruxal's analysis: ISERA Lifesciences Limited has announced a significant equity share issuance via…
Read the full analysis - iSERA Lifesciences Limited announces acquisition of shares through preferential allotment, with a total share capital increase of Rs. 8.48 crore, indicating strategic expansion plansInsider Trading / SASThigh impact
Cruxal's analysis: iSERA Lifesciences Limited has disclosed a preferential allotment of Rs. 8.48 crore…
Read the full analysis - SEBI Disclosure Indicates Share Acquisition by Promoter Pratap Dadasaheb Deshmukh at a 41.37% Discount to Market PriceInsider Trading / SASThigh impact
Cruxal's analysis: The company, ISERA Lifesciences Limited, has received SEBI approval for a share…
Read the full analysis - iSERA Lifesciences approves allotment of 161.82 million shares at Rs. 48.20 per share via preferential issue on October 1, 2026Company Updatelow impact
Cruxal's analysis: The company's Board of Directors approved the allotment of 161.82 million fully paid-up…
Read the full analysis - iSERA Lifesciences announces issuance of 1.62 crore equity shares via Share Swap at Rs. 48.20/share, impacting promoter and investor holdingsOthershigh impact
Cruxal's analysis: iSERA Lifesciences has approved a significant equity issuance of 1.62 crore shares on a…
Read the full analysis - iSERA Lifesciences Limited (formerly Covidh Technologies) passes key resolutions at AGM held on 29th September 2026, with all resolutions approved by requisite majority via e-voting and AGM voting.AGM/EGMmedium impact
Cruxal's analysis: iSERA Lifesciences Limited conducted its 34th AGM on 29th September 2026, where two…
Read the full analysis - We hereby submit the proceeding of the 34th AGMAGM/EGMmedium impact
- We hereby submit the Closure of Trading Window for iSEAR LifeSciences Limited (Formerly Known as Covidh Technologies LimitedInsider Trading / SASTlow impact
- iSERA Lifesciences Limited Announces 34th Annual General Meeting (AGM) Scheduled for September 29, 2026Company Updatelow impact
Cruxal's analysis: iSERA Lifesciences Limited has issued a formal notice for its 34th Annual General Meeting…
Read the full analysis - iSERA Lifesciences Ltd submits Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: iSERA Lifesciences Limited has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - iSERA Lifesciences Limited schedules 34th Annual General Meeting for September 29, 2026AGM/EGMlow impact
Cruxal's analysis: iSERA Lifesciences Limited has issued a notice for its 34th Annual General Meeting (AGM)…
Read the full analysis - iSERA Lifesciences Ltd files copy of newspaper publication with the exchangeCompany Updatelow impact
Cruxal's analysis: iSERA Lifesciences Limited, formerly known as Covidh Technologies Limited, has submitted…
Read the full analysis - iSERA Lifesciences Limited schedules 34th Annual General Meeting for September 29, 2026Otherslow impact
Cruxal's analysis: iSERA Lifesciences Limited has announced the scheduling of its 34th Annual General…
Read the full analysis - iSERA Lifesciences Limited Submits Monitoring Agency Report for Rights Issue Proceeds UtilizationCompany Updatelow impact
Cruxal's analysis: iSERA Lifesciences Limited has submitted its Monitoring Agency Report for the quarter…
Read the full analysis - iSERA Lifesciences Limited reports nil revenue and a net loss of 0.34 crore for the quarter ended June 30, 2026Resulthigh impact
Cruxal's analysis: iSERA Lifesciences Limited reported nil revenue from operations for the quarter ended…
Read the full analysis - iSERA Lifesciences Limited reports net loss of 33.62 lakh for Q1 FY2027 with zero revenue from operationsBoard Meetinghigh impact
Cruxal's analysis: iSERA Lifesciences Limited has released its unaudited financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.